Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048048 · ClinicalTrials.gov registry record · Phase 2
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00048048 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 65 participants.
The verdict
NCT00048048, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis. The anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.
Interventions
- DRUG methoxy polyethylene glycol-epoetin beta [Mircera]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2002-03 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048048
The ClinicalTrials.gov registry entry for NCT00048048 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which methoxy polyethylene glycol-epoetin beta [Mircera] is the first listed.
NCT00048048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048048 about?
NCT00048048 is a clinical study titled "A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.". This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis. The anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.
What is the current status of trial NCT00048048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2002-03. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00048048?
The interventions under investigation include: methoxy polyethylene glycol-epoetin beta [Mircera] (DRUG).
Who is sponsoring clinical trial NCT00048048?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.